New hope for tough breast cancers: targeted drug tested after standard treatment fails
Disease control
Ongoing
This study is for people with HER2-negative breast cancer who still have cancer cells after completing standard chemotherapy before surgery, which puts them at high risk of the cancer returning. It compares a newer targeted drug called sacituzumab govitecan against the doctor's u…
Phase: PHASE3 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC